Editor-in-Chief, Deputy Editor 2017-2019

 

Editor-in-Chief:

Tom MOREELS

 

Deputy Editor:

Nicolas LANTHIER

 

Expert opinion



Update of the Belgian Association for the Study of the Liver Guidelines for the Treatment of Chronic Hepatitis C Genotype 1 with Protease Inhibitors


Price: €10,00

Chronic hepatitis C virus (HCV) affects approximately 170 million people worldwide. Hepatitis C virusinduced cirrhosis remains the most common indication for liver transplantation and is a major contributor to the worldwide increase in the incidence of hepatocellular cancer (1). Among the six major genotypes, genotype 1 is the most common and difficult to treat. Treatment for this disease has consisted of therapies that stimulate the immune system and interfere in a nonspecific manner with viral replication. For the past decade, the standard of care for patients with chronic infection with genotype 1 HCV has been 48-week treatment of pegylated interferon (pegIFN) alfa and ribavirin (RBV). The observed rates of sustained virological response (SVR) with pegIFN and RBV therapy are 40-50% (2-5). Research has focused on therapies that inhibit HCV proteins that are essential for intracellular replication. These drugs are referred to as direct-acting antiviral agents (DAAs). Currently, boceprevir and telaprevir, which are 2 firstgeneration DAAs, are available for the treatment of genotype 1 chronic hepatitis C. These guidelines update the existing BASL guidelines (6) for the treatment of genotype 1 chronic hepatitis C. The current recommendations are based on published data of these new molecules published prior to 31 March 2012. [Product Details...]